Search 

HemoShear is a privately held biotechnology company that is changing the way drugs are discovered and developed, departing from traditional and often misleading scientific methods and animal studies in favor of translational tissue systems that accurately replicate human disease biology.  Its proprietary platform integrates best-in-class human disease systems, a comprehensive biorepository, interdisciplinary molecular and clinical disease expertise, and cutting-edge computational biology, together providing a unique and powerful lens to interpret biological mechanisms and human disease at a level not possible until now.  HemoShear’s drug discovery collaborations uncover new targets, elucidate previously unknown mechanisms, differentiate drug candidates, and predict efficacy and safety of drugs before entering the clinic.  HemoShear is collaborating to discover and develop new drugs with major pharmaceutical and biotechnology companies, five divisions of NIH and leading academic research institutions across several therapeutic areas, including oncology.

In November 2013, HemoShear announced a collaboration with NCI to initiate work to recreate the human tumor microenvironment in a physiologically relevant context that replicates human disease.  HemoShear has successfully completed the first stage of the NCI contract to create a tumor system that incorporates three essential cell-types, restores molecular signaling pathways and responds to three cancer treatments at human concentrations.  We know of no other systems that can assess drugs at human concentrations.   HemoShear is seeking $10 million from investors and/or pharmaceutical partners to engage in drug discovery collaborations and expand development of a wide range of tumor types and therapeutic approaches.